Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Nature Medicine

Volumn 14, Issue 12, 2008, Pages 1351-1356

  Engelman, Jeffrey A ^a,b,c   Chen, Liang ^d,e   Tan, Xiaohong ^d,e   Crosby, Katherine ^f   Guimaraes, Alexander R ^g   Upadhyay, Rabi ^g   Maira, Michel ^h   McNamara, Kate ^d,e   Perera, Samanthi A ^d,e   Song, Youngchul ^a   Chirieac, Lucian R ⁱ   Kaur, Ramneet ^a,c   Lightbown, Angela ^f   Simendinger, Jessica ^f   Li, Timothy ^b   Padera, Robert F ⁱ   García Echeverría, Carlos ^h   Weissleder, Ralph ^c,g   Mahmood, Umar ^g   Cantley, Lewis C ^b,c   Wong, Kwok Kin ^c,d,e   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e DANA FARBER HARVARD CANCER CENTER   (United States)

^f CELL SIGNALING TECHNOLOGY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; DOXYCYCLINE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN P110; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG POTENTIATION; LUNG ADENOCARCINOMA; LUNG CANCER; MICROSCOPY; MOUSE; MUTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS);

MAMMALIA; MURINAE;

EID: 57349194139     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1890     Document Type: Article

References (21)

1. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
2. Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485-495 (2006).
3. Li, D. et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12, 81-93 (2007).
4. Fisher, G.H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001).
5. Perl, A.K., Tichelaar, J.W. & Whitsett, J.A. Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res. 11, 21-29 (2002).
6. Yu, J. et al. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18, 1379-1387 (1998).
7. Fruman, D.A. et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 283, 393-397 (1999).
8. Brachmann, S.M., Ueki, K., Engelman, J.A., Kahn, R.C. & Cantley, L.C. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25, 1596-1607 (2005).
9. Maira, S.-M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual PI3K-mTor inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
10. Gupta, S. et al. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129, 957-968 (2007).
11. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
12. +/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 102, 10238-10243 (2005).
13. Yang, Y. et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 3, e2220 (2008).
14. She, Q.B. et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8, 287-297 (2005).
15. Mellinghoff, I.K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
16. Sharma, S.V., Fischbach, M.A., Haber, D.A. & Settleman, J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 12, 4392s-4395s (2006).
17. Engelman, J.A. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin. Cancer Res. 13, s4637-s4640 (2007).
18. Yeh, T.C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576-1583 (2007).
19. Lievre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
20. Jhawer, M. et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 68, 1953-1961 (2008).
21. Perez-Tenorio, G. et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13, 3577-3584 (2007).